Thomas Niel

Thomas Niel

InvestorPlace Contributor

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

Sell Into The Madness With Sundial Growers Stock

By Thomas Niel, InvestorPlace Contributor

With little backing the recent retail investor enthusiasm for SNDL stock, cash out if you own it, and avoid it if you don't.

With Workhorse Stock, It’s Hard to Fade the Hype

By Thomas Niel, InvestorPlace Contributor

Even as reality fails to match up with high expectations priced in by retail investors, it'll be a while before WKHS stock takes a tumble.

9 Meme Stocks That Social Media Won’t Shut Up About

By Thomas Niel, InvestorPlace Contributor

It may be fun to dabble in meme stocks. But, don't consider it a surefire path to investing profits. Keep this in mind before diving into these companies.

TransEnterix Stock Has Potential, But Wait for a Pullback

By Thomas Niel, InvestorPlace Contributor

So, after contrasting the opportunities and risks with TRXC stock, what's the play? It may be interesting at lower prices. But, for now, hold off buying.

Jack-of-All-Trends Ideanomics Is No Place to Invest Your Money

By Thomas Niel, InvestorPlace Contributor

But, is IDEX stock a worthwhile long-term play on multiple megatrends? Don't bet on it.

Zomedica Stock Could Rise Even Higher, But It’s Still a Gamble

By Thomas Niel, InvestorPlace Contributor

Bottom line: there's only call for ZOM stock: be careful, even if shares pull back from here.

Don’t Get FOMO; It’s Too Late to Jump Into Ocugen Stock

By Thomas Niel, InvestorPlace Contributor

Risk-hungry traders have profited greatly from the parabolic moves of OCGN stock, but if you don't own it yet, the ship's likely sailed.

Wait for the Madness to Settle Before Buying BlackBerry Stock

By Thomas Niel, InvestorPlace Contributor

The company may be making the right moves, by targeting opportunities in IoT, AI, and AV technology. But, until it shows meaningful success, it's not worth buying BB stock at today's still rich valuation.

These 3 Private Prison Stocks Could Surprise Following Biden’s EO

By Thomas Niel, InvestorPlace Contributor

To top it all off, this change will take years to play out. Investors may be overestimating the damage Biden's EO will do for prison stocks. Granted, reforms could speed up, impacting their ICE and state/local operations. But, these three private prison stocks could surprise going forward: CoreCivic (NYSE:CXW) The GEO Group (NYSE:GEO) Palantir (NYSE:PLTR)

Why “All Bets Are Off” on Tesla Stock

By Thomas Niel, InvestorPlace Contributor

Weighing the bulls' thesis against the bear case, it's tough to tell whether Tesla stock is ready to surge higher or sink lower.

Load More